ライフサイエンスコーパス: B-cell receptor

1 nly one autosome expresses a functional T or B cell receptor.

2 lation to B cells via co-engagement with the B cell receptor.

3 red with MOG by MOG-specific B cells via the B-cell receptor.

4 tes as secreted antibodies or as part of the B-cell receptor.

5 complexes including the CD19 subunit of the B-cell receptor.

6 ricted to rare B cells carrying HDM-specific B cell receptors.

7 g molecules downstream of the pre-B cell and B cell receptors.

8 g antibodies or bind particular Ig germ-line B-cell receptors.

9 pression of stereotyped IGHV4-39/IGKV1(D)-39 B-cell receptors.

10 igen accessibility by shielding antigen from B-cell receptor access.

11 Because stimulation of the B-cell receptor activates JAK2 in CLL cells and the JAK2

12 cing up to ~25-30 nm monotonically increases B-cell receptor activation.

13 tabilization, triggered by engagement of the B cell receptor, acts as a cue to release centrosome-ass

14 ing the roles of B cell precursor frequency, B cell receptor affinity for antigen, antigen avidity, a

15 of thresholds for B cell selection based on B cell receptor affinity.

16 The IgG3-1 subclass switch interacts with B cell-receptor affinity maturation and defects in the a

17 GCs are required for almost all B-cell receptor affinity maturation and will be a critic

18 es surveyed the activation status of the pre-B cell receptor and comprehensively investigated downstr

19 e found that glucocorticoids impair upstream B cell receptor and Toll-like receptor 7 signaling, redu

20 B cell receptors and surface-displayed peptide/MHCII com

21 by low frequencies of appropriate precursor B cell receptors and the complex maturation pathways req

22 B-cell compartment, and B-cell responses to B-cell receptor and IL-21 receptor engagement.

23 ase delta (PI3Kdelta), a linchpin in the pre-B-cell receptor and interleukin 7 receptor signaling pat

24 n that were enriched for factors involved in B-cell receptor and JAK/STAT signaling, the nonclassical

25 or other BTK mutations, and other targets in B-cell receptor and MYD88 signaling.

26 Targeting the B-cell receptor and phosphatidylinositol 3-kinase/mTOR s

27 CR4) on treatment decisions, indications for B-cell receptor and proteasome inhibitors, and future cl

28 CLL relies on the concomitant cooperation of B-cell receptor and Toll-like receptor signaling; inhibi

29 sting that SpA cross-linking of VH3 idiotype B-cell receptors and activation via attached peptidoglyc

30 s provide the antigen recognition portion of B-cell receptors and derivative antibodies.

31 tion of endogenous class I and class II HLA, B-cell receptor, and Fc receptor genes.

32 itory activity that reduced T-cell receptor, B-cell receptor, and interferon signaling in B cells.

33 s encoding signaling components that mediate B cell receptor- and or cytokine receptor-mediated signa

34 rthermore, we find that PTIP is required for B cell receptor- and T:B interaction-induced proliferati

35 protein (gp120), and the V-gene that encodes B-cell receptors/antibodies.

36 the 426c Env that activate germline-reverted B cell receptors are candidate immunogens for eliciting

37 These screens identified CD22, a canonical B cell receptor, as a negative regulator of phagocytosis

38 or survival via B-cell activating factor and B-cell receptor-associated pathways.

39 Here we aimed to target the B-cell receptor-associated protein CD79b by a T-cell rec

40 Such B cells experience both B cell receptor (BCR) activation and TLR engagement, lea

41 face receptor sialic acid (SA) to identify a B cell receptor (BCR) activation modality that proceeded

42 Diverse cellular signaling events, including B cell receptor (BCR) activation, are hypothesized to be

43 ating B cells can directly generate a mature B cell receptor (BCR) and bypass the requirement for a p

44 The antigen-binding variable regions of the B cell receptor (BCR) and of antibodies are encoded by e

45 B cell receptor (BCR) and T cell receptor (TCR) repertoi

46 responses via complex interactions with the B cell receptor (BCR) and Toll like receptor (TLR) pathw

47 emia (CLL) cells on signals derived from the B cell receptor (BCR) has encouraged the development of

48 However, engagement of the B cell receptor (BCR) induced both expression of IFITM3

49 rize transcriptional differences governed by B cell receptor (BCR) isotype and vaccine reactivity.

50 ng a Ubqln1(-/-) mouse strain, we found that B cell receptor (BCR) ligation of Ubqln1(-/-) B cells le

51 e Tec family of kinases and is essential for B cell receptor (BCR) mediated signaling.

52 in 2A (LMP2A), which has been described as a B cell receptor (BCR) mimic promoting malignant transfor

53 for instance, downstream of an autoreactive B cell receptor (BCR) or a transforming oncogene, can ca

54 ted with 2 or more mutations, and linked the B cell receptor (BCR) pathway to trisomy 12, an importan

55 ovax 23 and had impaired selection of the B1 B cell receptor (BCR) repertoire.

56 Donor B cell receptor (BCR) repertoires identified two bNAb li

57 Yet, infection of mice with limited B cell receptor (BCR) repertoires impaired the response,

58 Analysis of the B cell receptor (BCR) repertoires in six IMDs provides i

59 Next generation sequencing of B cell receptor (BCR) repertoires offers an additional s

60 same initial V(D)J rearrangement, but their B cell receptor (BCR) sequence may differ due to the acc

61 ion work together to produce antibody-coding B cell receptor (BCR) sequences for a remarkable diversi

62 B cell receptor (BCR) sequencing is a powerful tool for

63 idelalisib, and dasatinib, drugs that block B cell receptor (BCR) signaling and are used in the trea

64 These processes require B cell receptor (BCR) signaling and occur in bone marrow

65 B cells in sIgM (-/-) mice display increased B cell receptor (BCR) signaling as judged by increased l

66 However, the role of Rictor on B cell receptor (BCR) signaling as well as the underlyin

67 rge B cell lymphoma (DLBCL), which relies on B cell receptor (BCR) signaling for survival.

68 Considering the central role of B cell receptor (BcR) signaling in CLL pathobiology, it

69 express an array of inhibitory receptors and B cell receptor (BCR) signaling is stunted in atypical M

70 ts, PKCbetaI and PKCbetaII, functions in the B cell receptor (BCR) signaling pathway and contributes

71 ture B lineage selection have been linked to B cell receptor (BCR) signaling strength and environment

72 Chronic active B cell receptor (BCR) signaling, a hallmark of the activ

73 and PI3K signaling consistent with activated B cell receptor (BCR) signaling, although they do not ex

74 We surmise that, unlike B cell receptor (BCR) signaling, MYD88/IRAK signaling is

75 We discuss targeting of B cell receptor (BCR) signaling, with emphasis on identi

76 oma (PCNSL) harbors mutations that reinforce B cell receptor (BCR) signaling.

77 71 and found that components of the proximal B cell receptor (BCR) signalosome were enriched within t

78 nts' B cells fail to activate NF-kappaB upon B cell receptor (BCR) stimulation.

79 functions, including those regulated by the B cell receptor (BCR) through increased cytosolic Ca(2+)

80 Each B cell expresses a single B cell receptor (BCR)(1), and the diverse range of BCRs

81 , we have described a relationship among the B cell receptor (BCR), TLR9, and cytokine signals that r

82 Nevertheless, recent work has shown that B cell receptor (BCR)-antigen engagement in vitro can pr

83 t from that of conventional B cells, through B cell receptor (BCR)-dependent positive selection of fe

84 lated CD21 levels and diminished response to B cell receptor (BCR)-dependent stimulation.

85 The compounds inhibit B cell receptor (BCR)-mediated AKT phosphorylation (pAKT

86 beta) expression and correlatively inhibited B cell receptor (BCR)-mediated gammaherpesviral replicat

87 BTK plays an essential role in B cell receptor (BCR)-mediated signaling as well as Fcga

88 B lymphocytes through the specificity of the B cell receptor (BCR).

89 evels of B-lineage transcription factors and B cell receptor (BCR)/pre-BCR-signaling genes.

90 On antigen binding, B cell receptors (BCR) cluster on the plasma membrane an

91 e to external signals, such as in binding of B cell receptors (BCR) to antigen, which initiates signa

92 hroughput sequencing of transcripts encoding B cell receptors (BCR-seq) to quantitatively determine t

93 ct of CD23 expression on the early events of B-cell receptor (BCR) activation using CD23 knockout (KO

94 At high levels of B-cell receptor (BCR) activation, which may occur in ind

95 Here, we demonstrate activation of B-cell receptor (BCR) and canonical NF-kappaB signaling

96 ients harbor mutations in the interconnected B-cell receptor (BCR) and CXCR4 signaling pathways.

97 istically, we show that SPRY2 attenuates the B-cell receptor (BCR) and MAPK-Erk signaling by binding

98 Inhibitors of B-cell receptor (BCR) and pre-BCR signaling were success

99 Kinase inhibitors targeting the B-cell receptor (BCR) are now prominent in the treatment

100 We demonstrate that dominant IgG4(+) B-cell receptor (BCR) clones determined by next-generati

101 and regulates B-cell signaling by modulating B-cell receptor (BCR) clustering and internalization.

102 inimally activated or anergic in response to B-cell receptor (BCR) crosslinking in vitro.

103 ssion of Ahr in B cells is up-regulated upon B-cell receptor (BCR) engagement and IL-4 treatment.

104 B-cell receptor (BCR) engagement with surface-tethered a

105 Antigenic stimulation via the B-cell receptor (BCR) is a major driver of the prolifera

106 B-cell receptor (BCR) knock-in (KI) mouse models play an

107 We find that B-cell receptor (BCR) ligation drives switch-like Ras ac

108 Although inhibitors targeting the B-cell receptor (BCR) pathway have been successful in th

109 To investigate the effects of aging on B-cell receptor (BCR) repertoire evolution during an imm

110 - and light-chain genes results in a diverse B-cell receptor (BCR) repertoire including self-reactive

111 B-cell receptor (BCR) repertoire profiling is an importa

112 Rs) of more than 180 million human and mouse B-cell receptor (BCR) repertoire sequences.

113 major costimulatory molecule for amplifying B-cell receptor (BCR) responses.

114 ctivation markers, and are hyporesponsive to B-cell receptor (BCR) restimulation in vitro.

115 ion of spleen tyrosine kinase (SYK) in tonic B-cell receptor (BCR) signal-dependent diffuse large B-c

116 is a malignancy of mature B cells driven by B-cell receptor (BCR) signaling and activated primarily

117 B-cell lymphoma is characterized by aberrant B-cell receptor (BCR) signaling and constitutive nuclear

118 ese B-ALLs encode proteins implicated in pre-B-cell receptor (BCR) signaling and migration/adhesion,

119 FL cells remain highly dependent on B-cell receptor (BCR) signaling and on a specific cell m

120 HGAL protein also regulates B-cell receptor (BCR) signaling by directly binding to a

121 of lymphoma cell proteins and inhibits early B-cell receptor (BCR) signaling events critical for surv

122 mediated genomic modification to investigate B-cell receptor (BCR) signaling in cell lines of diffuse

123 In this study, we used chronic active B-cell receptor (BCR) signaling in diffuse large B-cell

124 Recent studies revealed the importance of B-cell receptor (BCR) signaling in maintaining MCL survi

125 Our work also pinpoints the regulation of B-cell receptor (BCR) signaling in the release of CLL ex

126 Targeting B-cell receptor (BCR) signaling is a successful therapeu

127 B-cell receptor (BCR) signaling is essential for the dev

128 Altered B-cell receptor (BCR) signaling might contribute to the

129 uggest a link between MYC overexpression and B-cell receptor (BCR) signaling molecules in B-NHL, sign

130 sine kinase and PI3K inhibitors that inhibit B-cell receptor (BCR) signaling pathway at proximal kina

131 Inhibition of the B-cell receptor (BCR) signaling pathway is a promising t

132 B-cell receptor (BCR) signaling pathways and interaction

133 Inhibition of B-cell receptor (BCR) signaling pathways in chronic lymp

134 endothelial cell angiogenesis, regulation of B-cell receptor (BCR) signaling, and the survival, activ

135 inked to chronic infection, which may induce B-cell receptor (BCR) signaling, resulting in aberrant B

136 Agents targeting B-cell receptor (BCR) signaling-associated kinases such

137 ll lymphoma (DLBCL) relies on chronic active B-cell receptor (BCR) signaling.

138 volunteers, the balance between the CD40 and B-cell receptor (BCR) signalling modulated IL-10 product

139 The disease is believed to be driven by B-cell receptor (BCR) signals generated by external anti

140 GHV-mutated with no restricted IGHV usage or B-cell receptor (BCR) stereotypy.

141 ronic lymphocytic leukemia (CLL) cells after B-cell receptor (BCR) stimulation and show that current

142 er resistance to ABT-199 can be conferred by B-cell receptor (BCR) stimulation, which is another impo

143 inhibited the activation of Akt kinase upon B-cell receptor (BCR) stimulation.

144 cell including autoantigen engagement of the B-cell receptor (BCR) with simultaneous type I interfero

145 ated to regulate signaling downstream of the B-cell receptor (BCR), Fc receptors (FcRs), and toll-lik

146 -surface product, the variable region of the B-cell receptor (BCR), otherwise known as idiotype.

147 increasingly used to query the antibody, or B-cell receptor (BCR), sequence repertoire, and the amou

148 nergy induced by continual engagement of the B-cell receptor (BCR), such as high expression of phosph

149 ells expressing the fully humanized gl3BNC60 B-cell receptor (BCR), we immunized mice carrying both t

150 IgH and IgL chains associate to form the B-cell receptor (BCR), which, upon antigen binding, acti

151 Mutations in genes promoting the tonic B-cell receptor (BCR)-->PI3K pathway (TCF3 and ID3) did

152 B-cell receptor (BCR)-activated B cells contribute to pa

153 Cell-autonomous B-cell receptor (BcR)-mediated signalling is a hallmark

154 detail how PDE4 inhibition downmodulates the B-cell receptor (BCR)-related kinases spleen tyrosine ki

155 y CCC criteria, 6 of 8 DLBCL PDX models were B-cell receptor (BCR)-type tumors that exhibited selecti

156 s initiated by the binding of antigen to the B-cell receptor (BCR).

157 imulation by restoring signaling through the B-cell receptor (BCR).

158 ying valency and mode of presentation to the B-cell receptor (BCR).

159 fied a subset of plasma cells that expresses B-cell receptors (BCR) specific for gluten peptides or t

160 surface of an antigen-presenting cell (APC), B cell receptors (BCRs) are gathered into microclusters

161 The B cell receptors (BCRs) for antigen express variable (V)

162 g and deletion, prevent highly self-reactive B cell receptors (BCRs) from populating the periphery.

163 Animal models of human antigen-specific B cell receptors (BCRs) generally depend on "inferred ge

164 stalk between Toll-like receptors (TLRs) and B cell receptors (BCRs) in the TI B cell immunity, we he

165 antibodies (sIg) or as membrane-bound (mIg) B cell receptors (BCRs) through alternative RNA splicing

166 B cell activation via B cell receptors (BCRs), a process requiring lipid rafts

167 igh affinity antibodies, the soluble form of B cell receptors (BCRs), that bind to and neutralize inv

168 the cell surface expression of HIV specific B cell receptors (BCRs).

169 rates preimmune Ig repertoires, expressed as B cell receptors (BCRs).

170 trimers is virtually impenetrable for murine B cell receptors (BCRs).

171 were disproportionally used to encode clonal B-cell receptors (BCRs) in the tumors.

172 L patients have stereotyped antigen-specific B-cell receptors (BCRs) with a high level of sequence ho

173 ." These cells express antigen-specific T or B cell receptors, but behave with innate characteristics

174 tion of B cells carrying somatically mutated B-cell receptors by follicular helper T (TFH) cells in g

175 CD19, a signaling component of the B cell receptor complex, is one of multiple regulators d

176 chains of immunoglobulin that determine the B cell receptor composition undergo stepwise rearrangeme

177 idylinositol (3,4,5)-trisphosphate (PIP3) on B cell receptor-containing early endosomes and proper so

178 nd TLR4 signaling, and partially rescued via B-cell receptor crosslinking.

179 The B-cell receptor enables individual B cells to identify d

180 ion elicits BTK-independent activation after B-cell receptor engagement, implying the formation of a

181 In A20 B cells transduced with TG2-specific B-cell receptor, epitope 2-expressing cells had poorer u

182 prototypical celiac patient-derived anti-TG2 B cell receptor equally reactive to human and mouse TG2.

183 3'RR distal part, including hs4, fine-tuned B-cell receptor expression in newly formed and naive B-c

184 The IgH 3'RR plays a pivotal role in early B-cell receptor expression, germ-line transcription prec

185 Inhibitors of the B-cell receptor for antigen signaling and antibodies aga

186 nopposed activation of B cells through their B-cell receptor for antigen, as seen in B cells lacking

187 B-cell receptors form ordered clusters to recruit kinase

188 Here we sequence recombined and expressed B cell receptor genes in several individuals to determin

189 These Mphi precursors have non-rearranged B-cell receptor genes and coexpress myeloid (GR1, CD11b,

190 njugate targeting the CD79b component of the B-cell receptor, has demonstrated activity as a single a

191 complementarity determining region 3 of each B cell receptor heavy chain in every patient repertoire

192 in general, or the expression of stereotyped B-cell receptor immunoglobulin defining subset #2 (IGHV3

193 gnal-transduction protein STAT5)(2-4) or pre-B-cell receptors in more mature cells (via activation of

194 mphadenopathy (>=5 cm) and refractoriness to B-cell receptor inhibitor (BCRi) therapy were significan

195 Other B-cell receptor inhibitors, second-generation proteasome

196 , we transferred B cells with germline VRC01 B cell receptors into congenic recipients to elucidate t

197 s proliferation, such that engagement of the B-cell receptor is important for malignant progression.

198 These include B-cell receptor, JAK/STAT, NF-kappaB, NOTCH, and Toll-li

199 B-cell receptor kinase inhibitor (KI) therapy represents

200 l concept, macromolecular recognition by the B cell receptor leading to deletion, anergy, receptor ed

201 e design of effective immunogens to activate B cell receptors leading to protective HIV-1 antibodies

202 BTK plays a critical role in the B cell receptor mediated inflammatory signaling in the r

203 anisms of cytotoxic T cell killing, inhibits B cell receptor-mediated gammaherpesviral replication in

204 B-cell receptor-mediated degradation of BCL6 was reduced

205 Activating precursor B cell receptors of HIV-1 broadly neutralizing antibodie

206 generation by V(D)J recombination of T- and B-cell receptors of any specific nucleotide sequence.

207 profiling revealed that the combination of a B-cell receptor or BCL2 inhibitor with OTX015 (a bromodo

208 B cells on selective in vitro stimulation of B-cell receptor or Toll-like receptor 9 pathways were re

209 Activation of the B cell receptor pathway activates lytic viral expression

210 or NFKBIZ amplification, frequent concurrent B-cell receptor pathway activation, and deregulation of

211 We hypothesised that dual B-cell receptor pathway blockade would be tolerable and

212 ndicated that the fibrils activated the CD40/B-cell receptor pathway in B-1a cells and induced a set

213 Inhibition of the B-cell receptor pathway, and specifically of Bruton tyro

214 phosphoinositide-3 kinase, downstream of the B-cell receptor pathway, approved in the United States f

215 s centered on agents that largely target the B-cell receptor pathway.

216 or Myb attenuated B cell action by altering B cell receptor pathways and MHCII cell surface presenta

217 for maintaining quiescence before precursor B cell receptor (pre-BCR) expression and for reestablish

218 Besides binding glycans, GAL1 is also a pre-B cell receptor (pre-BCR) ligand that induces receptor c

219 In developing B cells, pre-B cell receptor (pre-BCR) signals initiate immunoglobuli

220 ll precursor ALLs that differed by their pre-B cell receptor (pre-BCR) status were induced and displa

221 epigenetic landscape at Igk dictated by pre-B cell receptor (pre-BCR)-dependent Erk activation.

222 The pre-B-cell receptor (pre-BCR) is an important checkpoint of

223 present in 5%-7% of pediatric and 50% of pre-B-cell receptor (preBCR(+)) acute lymphocytic leukemia (

224 mbination and subsequent selection of T- and B-cell receptors provide useful tools to analyse and com

225 Clonal diagnostic markers (eg, unique T- or B-cell receptor rearrangements) are not available for NK

226 of infiltrating immune cell types, the T or B cell receptor repertoire, and direct the design of a p

227 We reveal a highly similar B-cell receptor repertoire among the four main human IgM

228 also impacts the B-cell compartment and the B-cell receptor repertoire in patients not affected by M

229 l individuals to determine the size of their B cell receptor repertoires, and the extent to which the

230 ive pancancer analyses of tumor-infiltrating B cell-receptor repertoires identified novel tumor immun

231 antigen-experienced and possess more diverse B-cell receptor repertoires compared to those of hypergl

232 nt in any given sample results in inaccurate B cell receptor sequence annotations, and in particular

233 body repertoires have led to an explosion in B cell receptor sequence data from donors with many diff

234 B cell receptor sequence diversity is generated by a ran

235 , coupled with assembled T cell receptor and B cell receptor sequences, we analyzed the functional pr

236 idden Markov Model (multi-HMM) framework for B cell receptor sequences.

237 apply the Haystack Heuristic to nine million B-cell receptor sequences obtained from nearly 100 indiv

238 B cell receptor sequencing confirmed that meningeal IgA(

239 als before and after kidney transplant using B cell receptor sequencing in a longitudinal clinical st

240 We used high-throughput B cell receptor sequencing of plasma cells produced foll

241 ific role for cytosolic Zn(2+) in modulating B cell receptor signal strength and positive selection.

242 ic lymphocytic leukemia (CLL) model impaired B cell receptor signaling and B cell migration, and sign

243 B cell receptor signaling and downstream NF-kappaB activ

244 hat activates the PI3K pathway downstream of B cell receptor signaling in B cells and Toll-like recep

245 ate the expression of many components of the B cell receptor signaling pathway and the receptors for

246 Inhibitors of B cell receptor signaling substantially changed the trea

247 these disorders include T cell receptor and B cell receptor signaling, cytokine signaling, skin barr

248 protein, which mimics constitutively active B cell receptor signaling, is required for EBV-induced l

249 whether the EBV protein LMP2A, which mimics B cell receptor signaling, is required for EBV-induced l

250 y expands and these MBCs show attenuation of B cell receptor signaling, loss of the B cell effector f

251 lent to acute activation of autoreactive pre-B cell receptor signaling, which engaged a deletional ch

252 ed cellular processes, including deregulated B cell receptor signaling, which we also identified in h

253 mediating energy metabolism, cell cycle, and B cell receptor signaling.

254 gulation of genes involved in pathways, like B cell receptor signaling.

255 in and tryptophan metabolism, autophagy, and B cell receptor signaling.

256 and FCRL2-5 activation along with increased B cell receptor signaling.

257 vel targeted therapies such as inhibitors of B-cell receptor signaling and B-cell lymphoma 2 have ope

258 oimmune diseases and may result from altered B-cell receptor signaling and dysregulated T-cell/regula

259 Previous studies suggested that chronic B-cell receptor signaling and increased NF-kappaB activa

260 or of Bruton tyrosine kinase (BTK), inhibits B-cell receptor signaling and is an effective, US Food a

261 l-molecule inhibitors of kinases involved in B-cell receptor signaling are an important advance in ma

262 controlled by constitutive activation of the B-cell receptor signaling component caspase recruitment

263 Although agents targeting B-cell receptor signaling have provided practice-changin

264 Constitutive B-cell receptor signaling leads to overexpression of the

265 ltage-gated proton channel-encoding gene and B-cell receptor signaling modulator, were associated wit

266 Newer oral B-cell receptor signaling pathway inhibitors are highly

267 lymphoma-2, and inhibitors of kinases in the B-cell receptor signaling pathway, like Bruton tyrosine

268 Unique attached oligomannoses activate B-cell receptor signaling pathways after engagement with

269 athways regulating estrogen, glucocorticoid, B-cell receptor signaling, and ATM signaling.

270 on's tyrosine kinase (BTK), is essential for B-cell receptor signaling, and most resistant cases carr

271 prisingly, NFAT activation is independent of B-cell receptor signaling, but mediated by an increased

272 E controls an extended program that includes B-cell receptor signaling, cellular metabolism, and epig

273 c constitutively activated CD40 receptor and B-cell receptor signaling, respectively.

274 ed miR-28 targets involved in cell-cycle and B-cell receptor signaling.

275 ntly deleted and include LYN, a regulator of B-cell receptor signaling.

276 te the survival of B cells by mimicking host B-cell receptor signaling.

277 s function with the innate immune system and B-cell receptor signaling.

278 ibuting to IgE class switch recombination or B-cell receptor signaling.

279 into vaccine induced antibody durability and B-cell receptor signaling.

280 ng those involved in B cell differentiation, B cell receptor signalling, activation of the NF-kappaB

281 Combinatorial disruption of B-cell receptor signalling and PI3K-AKT-mTOR axis leads

282 NKX2-3 induces B-cell receptor signalling by phosphorylating Lyn/Syk ki

283 ity is independent of CD4(+) T cell help and B cell receptor specificity and does not require B cell

284 ns were taken up by B cells independently of B-cell receptor specificity, indicating that HDM uptake

285 WASp-deficient B cells were hyperreactive to B cell receptor stimulation (BCR stimulation).

286 fically inhibits B cell responses induced by B cell receptor stimulation with antigen.

287 gamma2 and its downstream pathways following B cell receptor stimulation.

288 ich refers to a state of unresponsiveness to B cell receptor stimulation.

289 Here, we present LIBRA-seq (linking B cell receptor to antigen specificity through sequencin

290 (eNAMPT) is produced by CLL lymphocytes upon B-cell receptor, Toll-like receptor, and nuclear factor

291 pecific T and B lymphocytes using T cell and B cell receptor transgenic mice.

292 The B-cell receptor transmembrane activator and calcium modu

293 al cell receptor or gp42, which binds to the B-cell receptor, triggering gB-mediated fusion of the vi

294 The B cell receptor used in recognition can also be secreted

295 and single V-D, D-J gene combinations of the B-cell receptor variable region; increased frequency of

296 n individual's germline, which gives rise to B cell receptors via recombination, is known to vary sig

297 mice with Ag conjugated to an anti-CD180 Ab, B cell receptors were rapidly internalized.

298 the context of immune receptors, such as the B cell receptor, where dysregulated signaling can result

299 k (DSB) repair is critical for generation of B-cell receptors, which are pre-requisite for B-cell pro

300 identify rare naive human B cells expressing B cell receptors with similarity to iglb12.